Literature DB >> 3493981

Influence of the administration schedule on the therapeutic effect of interleukin-2.

J Vaage, J L Pauly, J P Harlos.   

Abstract

The local and systemic therapeutic effects of multiple peritumoral injections of recombinant human interleukin-2 (IL-2) were tested against the syngeneic, immunogenic mammary carcinoma MC2 implanted subcutaneously into C3H/He mice. Multiple (12) low-dose injections had a greater local therapeutic effect than the same total amount of IL-2 given in 2 injections. Peri-tumoral injections were equally effective in inhibiting the growth of the injected tumors in normal and in immunized mice. The systemic therapeutic effect was manifested by the inhibition of tumors implanted contra-laterally to the injected tumors, and was only discernible in non-immunized mice.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3493981     DOI: 10.1002/ijc.2910390421

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  5 in total

Review 1.  Pharmacokinetic and pharmacodynamic considerations in the development of therapeutic proteins.

Authors:  Iftekhar Mahmood; Martin D Green
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

Review 2.  Local and regional immunotherapy of cancer with interleukin 2.

Authors:  J Bubeník
Journal:  J Cancer Res Clin Oncol       Date:  1990       Impact factor: 4.553

3.  Local cytokine treatment of HPV16-associated tumours results in inhibition of their lung metastases.

Authors:  R Mikysková; J Bubenik; L Mendoza; V Vonka; M Smahel; J Símová; T Jandlová
Journal:  Clin Exp Metastasis       Date:  2000       Impact factor: 5.150

4.  Therapeutic efficacy of human recombinant interleukin-2 (TGP-3) alone or in combination with cyclophosphamide and immunocompetent cells in allogeneic, semi-syngeneic, and syngeneic murine tumors.

Authors:  K Ootsu; K Gotoh; T Houkan
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

5.  Combination therapy of colon carcinoma 26 in mice with recombinant human interleukin-2 and interferon-alpha A/D: occurrence of large granular cells in the tumor.

Authors:  Y Sakura; K Ootsu; A Shino
Journal:  Jpn J Cancer Res       Date:  1989-09
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.